| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
|
Medicine details |
|
| Medicine name | nivolumab (Opdivo®) |
| Formulation | 10 mg/mL concentrate for solution for infusion |
| Reference number | 2624 |
| Indication | As monotherapy for the treatment of squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/04/2017 |
| NICE guidance | |